Endoscopic Ultrasound-guided RadioFrequency Ablation for the Treatment Pancreatic NeuroEndocrine Neoplasms

NACompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 1, 2019

Primary Completion Date

January 1, 2024

Study Completion Date

February 1, 2024

Conditions
Neuroendocrine TumorsNeuroendocrine CarcinomaPancreas NeoplasmNeuroendocrine Tumor Gastrointestinal, Hormone-Secreting
Interventions
DEVICE

EUS guided radiofrequency ablation

The EUS-RFA system (Taewoong, Seoul, Korea) utilized for EUS-RFA consists of an 19-gauge needle electrode (140-cm long), a radiofrequency generator, and an inner cooling system that circulates chilled saline solution during the RFA procedure. The inner metal part is insulated over its entire length, with the exception of the terminal 5 to 20mm for energy delivery. The needle electrode is attached to a radio frequency current generator (VIVA RF generator; Taewoong) and to a cooling pump. The generator, in addition to providing radio frequency current, allows the control of physical power and impedance parameters.

Trial Locations (2)

00168

Fondazione Policlinico Universitario Agostino Gemelli, Roma

00136

Universita' del Sacro Cuore, Rome

All Listed Sponsors
lead

Catholic University of the Sacred Heart

OTHER

NCT03834701 - Endoscopic Ultrasound-guided RadioFrequency Ablation for the Treatment Pancreatic NeuroEndocrine Neoplasms | Biotech Hunter | Biotech Hunter